The University of Oxford and Serum Institute of India (SII) have developed a malaria vaccine, which has been recommended for use by the World Health Organization (WHO). The R21/Matrix-M vaccine can be produced at a large scale and low cost, making it accessible to countries with a high malaria burden.
